Mayne Pharma Group Limited
MAYNFOTCHealthcare● Active
$1.55
$-0.05(-3.13%)
Market Cap$125931032
P/E Ratio—
52W High$4
52W Low$1.4
Mayne Pharma Group Limited (MAYNF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MAYNF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 22, 2026EPS Actual
-$0.10
Est. -$0.01 · -837.2%
Revenue
$0.14B
Est. $0.14B · -0.0%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 22, 2026
After Market Close
▼ Miss EPS
MAYNF reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.01B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 20, 2026 | -$0.21 | — | — | — | $0.13B | — |
| ▼ Q1 FY2026 | Feb 22, 2026 | -$0.01 | -$0.10 | -837.2% | $0.14B | $0.14B | -0.0% |
| ▼ Q3 FY2025 | Aug 24, 2025 | $0.00 | -$0.56 | -14403.8% | $0.13B | $0.12B | +11.1% |
| ▼ Q1 FY2025 | Feb 24, 2025 | -$0.08 | -$0.20 | -158.5% | $0.13B | $0.12B | +7.4% |
| ▼ Q3 FY2024 | Aug 22, 2024 | -$0.15 | -$0.88 | -489.5% | $0.13B | $0.13B | -0.7% |
| ▼ Q2 FY2024 | May 13, 2024 | -$0.31 | -$0.59 | -88.8% | $0.13B | $0.11B | +16.7% |
| ▼ Q2 FY2023 | Jun 30, 2023 | -$0.38 | -$1.37 | -260.4% | $0.05B | $0.12B | -52.5% |
| ▼ Q4 FY2022 | Dec 31, 2022 | -$0.55 | -$1.12 | -103.2% | $0.07B | $0.05B | +27.3% |
Q3 FY2026
Aug 20, 2026
EPS Actual
—
EPS Est.
-$0.21
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 22, 2026Miss
EPS Actual
-$0.10
EPS Est.
-$0.01
EPS Surpr.
-837.2%
Revenue
$0.14B
Q3 FY2025
Aug 24, 2025Miss
EPS Actual
-$0.56
EPS Est.
$0.00
EPS Surpr.
-14403.8%
Revenue
$0.13B
Q1 FY2025
Feb 24, 2025Miss
EPS Actual
-$0.20
EPS Est.
-$0.08
EPS Surpr.
-158.5%
Revenue
$0.13B
Q3 FY2024
Aug 22, 2024Miss
EPS Actual
-$0.88
EPS Est.
-$0.15
EPS Surpr.
-489.5%
Revenue
$0.13B
Q2 FY2024
May 13, 2024Miss
EPS Actual
-$0.59
EPS Est.
-$0.31
EPS Surpr.
-88.8%
Revenue
$0.13B
Q2 FY2023
Jun 30, 2023Miss
EPS Actual
-$1.37
EPS Est.
-$0.38
EPS Surpr.
-260.4%
Revenue
$0.05B
Q4 FY2022
Dec 31, 2022Miss
EPS Actual
-$1.12
EPS Est.
-$0.55
EPS Surpr.
-103.2%
Revenue
$0.07B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.01 | $0.01 | $0.01 | 1 |
| Q2 FY2024 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Q4 FY2023 | $-0.44 | $-0.44 | $-0.44 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2025 | $0.2B | $0.2B | $0.2B | 1 |
| Q2 FY2025 | $0.3B | $0.3B | $0.3B | 1 |
| Q2 FY2024 | $0.3B | $0.3B | $0.3B | 1 |
| Q4 FY2023 | $0.2B | $0.2B | $0.2B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 22, 2026 | -837.2% | $1.86 | $1.86 | +0.00% |
| ▼ Q3 FY2025 | Aug 24, 2025 | -14403.8% | $3.29 | $3.29 | +0.00% |
| ▼ Q1 FY2025 | Feb 24, 2025 | -158.5% | $4.60 | $4.60 | +0.00% |
| ▼ Q3 FY2024 | Aug 22, 2024 | -489.5% | $2.76 | $2.76 | +0.00% |
| ▼ Q2 FY2024 | May 13, 2024 | -88.8% | $4.48 | $4.26 | -4.91% |
| ▼ Q2 FY2023 | Jun 30, 2023 | -260.4% | $2.57 | $2.57 | +0.00% |
| ▼ Q4 FY2022 | Dec 31, 2022 | -103.2% | $0.13 | $0.13 | +0.00% |
| ▼ Q2 FY2022 | Jun 30, 2022 | -1143.5% | $0.16 | $0.16 | -2.50% |
Q1 FY2026+0.00%
Report Date
Feb 22, 2026
EPS Beat/Miss
-837.2%
Price Before
$1.86
Price After
$1.86
Q3 FY2025+0.00%
Report Date
Aug 24, 2025
EPS Beat/Miss
-14403.8%
Price Before
$3.29
Price After
$3.29
Q1 FY2025+0.00%
Report Date
Feb 24, 2025
EPS Beat/Miss
-158.5%
Price Before
$4.60
Price After
$4.60
Q3 FY2024+0.00%
Report Date
Aug 22, 2024
EPS Beat/Miss
-489.5%
Price Before
$2.76
Price After
$2.76
Q2 FY2024-4.91%
Report Date
May 13, 2024
EPS Beat/Miss
-88.8%
Price Before
$4.48
Price After
$4.26
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
-260.4%
Price Before
$2.57
Price After
$2.57
Q4 FY2022+0.00%
Report Date
Dec 31, 2022
EPS Beat/Miss
-103.2%
Price Before
$0.13
Price After
$0.13
Q2 FY2022-2.50%
Report Date
Jun 30, 2022
EPS Beat/Miss
-1143.5%
Price Before
$0.16
Price After
$0.16
Avg Miss Reaction-0.93%
Beat Rate0 / 8 quarters
Largest Move-4.91% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MAYNF ends December
Mayne Pharma Group Limited (MAYNF) most recently reported earnings on February 22, 2026 for Q1 FY2026, posting EPS of $-0.10 — missing the analyst consensus of $-0.01 by -837.2%. The next MAYNF earnings date is expected around September 1, 2026.
Each quarter, investors track MAYNF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MAYNF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MAYNF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MAYNF earnings · 5 questionsMayne Pharma Group Limited's next earnings report is expected around September 1, 2026. MAYNF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MAYNF historically reports after market close (AMC).
MAYNF earnings datewhen is MAYNF earningsMAYNF next earnings datewhen does MAYNF report earningsMAYNF earnings calendar
▸ Source: FMP · Mayne Pharma Group Limited SEC filings · US GAAP · Mayne Pharma Group Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026